Dr. Gardner was the founding CEO of Akebia Therapeutics, Inc. in 2007, following twenty-three years of pharmaceutical discovery and development work at Procter & Gamble Pharmaceuticals. As CEO of Akebia, Read More

Dr. Peters guided the early preclinical and clinical development of AKB-9778 while at Akebia and Aerpio, and currently leads scientific discovery and translational development for Aerpio. He was formerly the Read More

Prior to joining Aerpio in 2013, Dr. Brigell was Executive Director of Translational Medicine, Ophthalmology at Novartis Institutes of BioMedical Research and held roles of increasing responsibility at Parke-Davis/Pfizer in Read More

Brandi is a diplomat of the American Board of Toxicology with 18 years of nonclinical toxicology experience. Dr. Soldo leads nonclinical exploratory safety/PK and GLP IND-enabling through Phase 3-support ADME, Read More

Ms. Marek is an active CPA and brings to Aerpio over 26 years of global and public company experience in Financial Reporting, Financial Planning and Analysis (FP&A) and Internal Audit.  Read More